Page 7 - Biocon

Biocon's Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

Shaw was picked from among 46 award winners from 41 countries and territories vying for the global title

Biocon MD Kiran Mazumdar-Shaw named EY World Entrepreneur Of The Year

The Biocon MD was picked from among 46 nominations from 41 countries

Biocon rallies 6%, hits record high on favourable ruling from US PTAB

Biocon's partner Mylan received a favourable ruling from U.S. Patent and Trademark Appeal Board (PTAB) on Sanofi's four device patents for Lantus SoloSTAR.

Biocon gets DCGI nod for CytoSorb device to treat Covid-19 patients

CytoSorb therapy reduces cytokine storm and the inflammatory response in Covid-19 patients through blood purification so that injury to organs may be mitigated or prevented

Logging in with facemasks: Offices look different as staff returns to work

Office life in these cities resumed on Monday, albeit cautiously and with full knowledge of the need to maintain social distancing.

Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD

In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022

MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall

All that happened in the markets today

Biocon shares slump over 4% as profit declines 42% in March quarter

The company's revenue, however, saw a muted growth of 6 per cent as compared to Q4 of FY19

Market Ahead, May 11: Top factors that could guide markets this week

Around 50 companies including the likes of Maruti Suzuki, Nestle, Dr Reddy's Labs, Biocon, and Bandhan Bank are scheduled to announce their March quarter results.

Mumbai docs try Biocon and Roche's biologic drugs on critical Covid cases

Two repurposed drugs for rheumatoid arthritis and psoriasis are being tried on over 100 patients in Mumbai

MSCI India rebalancing to stoke FPI inflows to the tune of Rs 1,900 cr

The rebalancing is scheduled to take place on May 12 and the changes will become effective from June 1

India Inc wants govt to shift focus to economy amid Covid-19 outbreak

CEOs warn of economic depression, say need to work within new normal

Biocon gains 5% as two Bengaluru facilities receive EIR from USFDA

The stock was trading close to its all-time high level of Rs 359, touched in September 2018

Biocon, Mylan launch Fulphila, a biosimilar Pegfilgrastim in Australia

CEO of Biocon Biologics, Dr Christiane Hamacher said, Fulphila, co-developed by Biocon Biologics and Mylan, is the third biosimilar to be commercialised in Australia

Malaysia plant boosts Biocon prospects in US and other key markets

Firm seen benefiting from operating leverage, biologic sales by FY22

Biocon's US prospects get a boost after company receives EIR from USFDA

The insulin patent win, clearance of Malaysian unit and oncology biosimilar filing are triggers

Biocon gains 5% as manufacturing unit in Malaysia gets EIR from USFDA

Biocon Sdn Bhd, a subsidiary of Biocon, received the EIR from the USFDA for the pre-approval inspection of its insulin manufacturing facility in Malaysia, for insulin glargine

Build to last

In the second part of a series, the author notes down some lessons for start-ups

Biocon: Fresh biosimilar opportunities to give a boost to its US prospects

The insulin patent win and filing of another oncology biosimilar in the US to drive earnings

Biocon receives EIR from USFDA for good manufacturing practice inspection

"We remain committed to global standards of quality and compliance," company spokesperson said